BioStacks

Mineral

Vanadium

Evidence

Preliminary

Reviewed May 2026

Evidence: 1 of 5 (Preliminary)

3 studies cited

What the evidence says

Vanadium is an ultra-trace mineral with insulin-mimetic properties demonstrated in animal and in vitro models. A handful of small human trials (n=6–16) in type 2 diabetics using high-dose vanadyl sulfate (100–150 mg/day, ~30–50 mg elemental vanadium) showed modest improvements in insulin sensitivity (Cohen 1995, Halberstam 1996, Goldfine 2000, Cusi 2001).

Insulin-mimetic in animal models; only a few tiny human trials (n=5–16) at doses far above UL. No evidence for benefit in healthy individuals

Supports

MetabolismPreliminary
General HealthPreliminary
MusclePreliminary

Top Vanadium supplements

1/5

Preliminary

3

RCTs reviewed

1

Null result

Skip. The blood-sugar claims rest on a handful of tiny old trials with GI side effects. Not even classified as essential for humans.

Vanadium is not classified as essential for humans. The diabetes-marketing case rests on small, decades-old trials at high doses with poor tolerability. Bodybuilding insulin-mimetic claims have no clinical basis.

Research dossier

Clinical research on Vanadium

3 trials reviewed across 3 indications.

Strongest evidence

Blood sugar regulation

Preliminary

Mechanism

Vanadium compounds inhibit protein-tyrosine phosphatases and produce insulin-mimetic and insulin-sensitizing effects in cell and animal models. The translatable human signal sits in a handful of small old diabetes trials.

The diabetes case rests on a few short trials of vanadyl sulfate at 100–150 mg/day in groups of 8–11 patients. Small effects on hepatic insulin sensitivity were reported. None of these trials are large enough or long enough to establish efficacy, and the GI side-effect profile at active doses limits practical use. There is no replication at scale and no inclusion in any modern diabetes guideline.

Even if a real signal exists in diabetes, the doses used in trials carry tolerability problems. There is no case for vanadium in non-diabetic adults.

Trials cited

  • Vanadyl sulfate in type 2 diabetes

    mixed · RCT

    Goldfine et al., 1995, Journal of Clinical Endocrinology & Metabolismn=8

    Eight adults with type 2 diabetes took 100 mg/day of vanadyl sulfate for four weeks. Fasting glucose fell modestly and hepatic insulin sensitivity improved. The signal is real at this dose, but the trial is tiny, short, and uses a dose that produces meaningful GI side effects.

    Small sample, short duration, high dose with substantial GI complaints. Not a basis for routine use even in diabetes — it is an old proof-of-concept, not a translatable therapy.

  • Vanadyl sulfate metabolic effects in T2D

    mixed · RCT

    Cusi et al., 2001, Journal of Clinical Endocrinology & Metabolismn=11

    Eleven adults with type 2 diabetes took 150 mg/day vanadyl sulfate for six weeks. Hepatic insulin sensitivity improved; peripheral insulin sensitivity did not change consistently. GI side effects limited tolerability. The story is similar to Goldfine 1995 — a partial signal at a poorly tolerated dose in a tiny sample.

    Trials in this size range cannot establish efficacy or safety adequately. The pattern of GI intolerance at supplement doses persisted.

General health

Mechanism

Vanadium is found in trace amounts in many foods (mushrooms, shellfish, black pepper, parsley, dill). No human deficiency syndrome has been characterized; vanadium is not classified as essential for humans.

Vanadium is not on the essential-nutrient list for humans. There are no clinical trials supporting general-health benefits and no reported deficiency syndrome to address. The absence of evidence here is informative — if vanadium mattered for health in healthy adults, dietary inadequacy would have been documented somewhere by now.

Routine supplementation in healthy adults is not justified by the available evidence.

Strength and body composition

Mechanism

The marketing claim invokes vanadium's insulin-mimetic action to drive nutrient partitioning. That logic relies on cell-culture findings, not human muscle-protein outcomes.

The only direct trial in resistance-trained athletes (Fawcett 1996) found no benefit on strength or body composition over 12 weeks at roughly 35–40 mg/day. The bodybuilding-supplement category continues to sell vanadyl sulfate; the actual data does not support it.

Not effective for the marketed strength and body-composition outcomes in athletes.

  • Vanadyl sulfate in resistance-training athletes

    Null · RCT

    Fawcett et al., 1996, International Journal of Sport Nutritionn=31

    Thirty-one resistance-trained athletes took roughly 35–40 mg/day vanadyl sulfate for 12 weeks. No meaningful improvement in strength or body composition compared with placebo. The bodybuilding insulin-mimetic story does not survive a controlled test.

    The bodybuilding marketing case for vanadium is not supported by the only direct trial in trained athletes.

3 forms of Vanadium compared

  • Vanadyl sulfate

    Modest oral absorption (estimated under 10%)

    Best forThe form used in essentially all human trials; sold OTC in bodybuilding and diabetes-adjacent supplements

    Tested doses (100–150 mg/day) commonly produce GI side effects. The bodybuilding-dose products at 7.5–10 mg are sub-therapeutic relative to even the questionable diabetes data.

  • Sodium vanadate / sodium metavanadate

    Variable

    Best forInvestigational form used in some early diabetes trials and biochemistry research

    Less common in retail products. The case for it over vanadyl sulfate in humans is not established.

  • BMOV (bis(maltolato)oxovanadium)

    Improved over vanadyl sulfate in animal data

    Best forInvestigational organic vanadium complex; pre-clinical only

    Not available in retail supplements at scale; clinical evidence in humans is limited.

Are you deficient? Symptoms, risk groups, lab tests

Vanadium is not classified as essential for humans. There is no defined RDA, no documented deficiency syndrome, and no dietary inadequacy concern.

Common symptoms

  • No characterized human deficiency syndrome

Who is at risk

  • None established

    Because vanadium is not essential for humans, there is no recognized at-risk population for deficiency.

Lab markers

  • Serum or urinary vanadium

    Not part of any routine clinical assessment. Useful only in occupational toxicology contexts (vanadium pentoxide industrial exposure), not for deficiency screening.

Side effects and drug interactions

Side effects

  • Gastrointestinal upset

    Common · Reported at doses used in clinical trials; less common at the 7.5–10 mg doses in retail supplements

    Nausea, abdominal cramping, and diarrhea are the most common and dose-limiting effects in the diabetes trials at 100–150 mg/day vanadyl sulfate.

  • Green tongue discoloration

    Uncommon

    A cosmetic but characteristic effect at higher doses of vanadyl sulfate.

  • Renal and hepatic accumulation concerns

    Uncommon

    Animal toxicology data raise concerns about long-term tissue accumulation. Long-term human safety at supplement doses has not been established.

  • Occupational pulmonary toxicity

    Severe

    Inhaled vanadium pentoxide (industrial dust) is a recognized occupational respiratory hazard. Not relevant to oral supplement use but worth flagging.

Drug interactions

  • Additive effect

    insulinsulfonylureasmetformin

    Vanadium's insulin-mimetic effects could theoretically add to glucose-lowering medication, increasing hypoglycemia risk.

    Diabetics on glucose-lowering therapy should not add vanadium without clinician oversight. The risk-benefit case is poor.

  • Other

    anticoagulants

    Limited evidence of platelet effects with vanadium compounds. Not well characterized at supplement doses.

    Be cautious if taking warfarin or other anticoagulants and considering high-dose vanadium products.

Other critical caveats
  • Vanadium is not classified as essential for humans. There is no RDA, no documented deficiency syndrome, and no general-health rationale for supplementation.
  • The diabetes evidence base is small, old, and dose-limited by GI side effects. Modern diabetes guidelines do not recommend vanadium in any form.
  • The bodybuilding insulin-mimetic case is not supported by the only controlled trial in trained athletes (Fawcett 1996), which found no benefit on strength or body composition.
Frequently asked
  • Should I take vanadium for blood sugar control?
    No. The clinical evidence is a few short trials in groups of 8–11 patients at doses (100–150 mg/day) that commonly cause GI side effects. The signal is modest and unreplicated at scale. Modern diabetes management has well-evidenced options that do not carry this trade-off.
  • Is vanadium essential for humans?
    No. Vanadium is essential in some animal species but is not classified as essential for humans. There is no defined RDA, no recognized deficiency syndrome, and no dietary inadequacy to address.
  • Does vanadium build muscle?
    The only direct trial in resistance-trained athletes found no improvement in strength or body composition over 12 weeks. The bodybuilding marketing for vanadyl sulfate continues, but the controlled-trial data does not support it.
  • Is vanadium dangerous?
    At typical retail supplement doses (7.5–10 mg), acute risk appears low but long-term safety is not well characterized. At the higher 100–150 mg doses used in diabetes trials, GI side effects are common and there are tissue-accumulation concerns from animal data. Industrial inhalation exposure (vanadium pentoxide) is a separate, well-recognized respiratory hazard.

References

  1. 01NIH Office of Dietary Supplements — Dietary Supplements for Diabetes (vanadium section)
  2. 02Linus Pauling Institute — Vanadium

Last reviewed2026-05-07